The interferon-alpha revival in CML
M Talpaz, J Mercer, R Hehlmann - Annals of hematology, 2015 - Springer
Interferon-alpha (IFNα) was once the standard of frontline treatment for chronic myeloid
leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and …
leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and …
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintas-Cardama, J Mercer… - Leukemia, 2013 - nature.com
Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
The role of interferon-alpha in the treatment of chronic myeloid leukemia
LA Kujawski, M Talpaz - Cytokine & growth factor reviews, 2007 - Elsevier
Biological agents have long been used in the treatment of cancer, and interferon-alpha was
the first human cytokine to be widely studied in this setting. Chronic myeloid leukemia (CML) …
the first human cytokine to be widely studied in this setting. Chronic myeloid leukemia (CML) …
Interferon alpha for treatment of chronic myeloid leukemia
B Simonsson, H Hjorth-Hansen… - Current drug …, 2011 - ingentaconnect.com
Treatment of chronic myeloid leukemia (CML) with interferon-alpha (IFN-α) was introduced
in the early 1980s. Several clinical trials showed a survival advantage for patients treated …
in the early 1980s. Several clinical trials showed a survival advantage for patients treated …
Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition
M Talpaz - Seminars in hematology, 2001 - Elsevier
The cytokine interferon-alfa (IFN-α) has substantial activity in chronic myeloid leukemia
(CML) and is the nontransplant standard of care for chronic-phase disease. When used as …
(CML) and is the nontransplant standard of care for chronic-phase disease. When used as …
Interferon in chronic myeloid leukaemia: past and future
F Guilhot, L Roy, PJ Saulnier, J Guilhot - Best practice & research Clinical …, 2009 - Elsevier
Imatinib has revolutionized the therapy of chronic myeloid leukaemia. However the complete
eradication of leukaemic stem cells is still a matter of discussion. Interferon (IFN) has been …
eradication of leukaemic stem cells is still a matter of discussion. Interferon (IFN) has been …
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after …
A Hochhaus, B Druker, C Sawyers… - Blood, The Journal …, 2008 - ashpublications.org
Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for
chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML …
chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML …
Imatinib and beyond—the new CML study IV: A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after …
U Berger, G Engelich, A Reiter, A Hochhaus… - Annals of …, 2004 - Springer
Management decisions for patients with chronic myeloid leukemia (CML) have become
remarkably complex due to a variety of highly effective treatment options. Therapy for …
remarkably complex due to a variety of highly effective treatment options. Therapy for …
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia
A Burchert, MC Müller, P Kostrewa, P Erben… - Journal of clinical …, 2010 - ascopubs.org
Purpose Imatinib induces sustained remissions in patients with chronic myelogenous
leukemia (CML), but fails to eradicate CML stem cells. This is of major concern regarding the …
leukemia (CML), but fails to eradicate CML stem cells. This is of major concern regarding the …
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien, F Guilhot, RA Larson… - … England Journal of …, 2003 - Mass Medical Soc
Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …